Compare SNDX & SPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDX | SPH |
|---|---|---|
| Founded | 2005 | 1945 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.4B |
| IPO Year | 2014 | 1996 |
| Metric | SNDX | SPH |
|---|---|---|
| Price | $23.84 | $20.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $84.17 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 110.2K |
| Earning Date | 05-25-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 6.32% |
| EPS Growth | 11.56 | ★ 42.11 |
| EPS | N/A | ★ 0.69 |
| Revenue | $172,352,000.00 | ★ $1,432,518,000.00 |
| Revenue This Year | $112.05 | $2.06 |
| Revenue Next Year | $51.24 | $1.64 |
| P/E Ratio | ★ N/A | $29.81 |
| Revenue Growth | ★ 627.84 | 7.94 |
| 52 Week Low | $8.59 | $17.30 |
| 52 Week High | $25.16 | $21.72 |
| Indicator | SNDX | SPH |
|---|---|---|
| Relative Strength Index (RSI) | 65.41 | 57.14 |
| Support Level | $19.46 | $20.00 |
| Resistance Level | $25.16 | $20.59 |
| Average True Range (ATR) | 1.24 | 0.44 |
| MACD | 0.22 | -0.03 |
| Stochastic Oscillator | 80.34 | 69.33 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Suburban Propane Partners LP distributes propane, renewable propane, renewable natural gas (RNG), fuel oil, refined fuels, and markets natural gas and electricity in deregulated markets. It produces and invests in low-carbon fuel alternatives. The company installs and services home comfort heating and ventilation equipment and distributes fuel oil, kerosene, diesel, and gasoline to about 25,000 residential and commercial customers mainly in the U.S. northeast. It operates three segments: Propane, Fuel Oil and Refined Fuels, and Natural Gas and Electricity, with the Propane segment generating the majority of revenue. Propane, a by-product of natural gas processing and petroleum refining, is a clean-burning energy source known for transportability and ease of use.